Latest Valeant Pharmaceuticals International Inc. Stories
LAVAL, Quebec, May 21, 2013 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) today announced the election of ten directors nominated at its 2013 annual meeting of shareholders today. The detailed results of the vote for the election of directors are set out below: Name For Withheld ---- --- -------- Ronald H. Farmer 235,731,934 1,964,748 Robert A. Ingram...
LAVAL, Quebec, May 20, 2013 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) today announced members of its senior management team will make a presentation at the 34(th) Annual Goldman Sachs Healthcare Conference on Tuesday, June 11, 2013 at 9:20 a.m. PT. The conference will be held at the Terranea Resort in Los Angeles, CA. A live webcast and audio archive of the presentation will be available on the company's Web site at www.valeant.com. Click...
LAVAL, Quebec, May 15, 2013 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) announced that Dr. Laurence Paul has resigned from Valeant's Board of Directors due to expanded business, philanthropic, and personal commitments. Dr. Paul was originally elected to Biovail Corporation's Board of Directors in June 2002 where he served in several capacities, including heading at various times the audit and compensation committees and multiple special...
LAVAL, Quebec, May 13, 2013 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) today announced that it will conduct a live webcast of the company's annual meeting of shareholders. The meeting and webcast will be held on Tuesday, May 21, 2013, at 9:00 a.m. ET at the International Headquarters, Laval Office: 2150 Saint Elzear Blvd. West, Laval Quebec, Canada H7L 4A8. Only shareholders of record at the close of business on the record date will be...
LAVAL, Quebec, May 10, 2013 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) announced today that it has provided additional information related to the proposal to continue Valeant into British Columbia (the "Continuance") under the British Columbia Business Corporations Act (the "BCBCA"). The Continuance is being presented for shareholder approval at Valeant's 2013 Annual Meeting of Shareholders to be held on Tuesday, May 21, 2013. If the...
LAVAL, Quebec, May 2, 2013 /PRNewswire/ -- 2013 First Quarter Total Revenue $1.068 billion; an increase of 25% over the prior year 2013 First Quarter Product Sales $1.039 billion; an increase of 38% over the prior year Organic growth (same store sales) was 6%, excluding the impact from generics, primarily BenzaClin and Cesamet Pro forma organic growth was 4%, excluding the impact from generics, primarily BenzaClin and Cesamet 2013 First Quarter GAAP EPS Loss of $0.09; Cash...
PARSIPPANY, N.J., and MONTREAL, May 1, 2013 /PRNewswire/ -- Actavis, Inc. (NYSE: ACT), and Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) today announced that Actavis Specialty Brands (the "Company") has acquired worldwide rights to Valeant's Metronidazole 1.3% Vaginal Gel antibiotic development product, a topical antibiotic for the treatment of bacterial vaginosis. Under the terms of the agreement, Actavis Specialty Brands is acquiring the product for...
LAVAL, Quebec, April 25, 2013 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) ("Valeant") today announced the expiration of the tender offer (the "Offer") by a subsidiary of Valeant Pharmaceuticals International ("VPI") to purchase all of the outstanding shares of Obagi Medical Products, Inc. (NASDAQ: OMPI) ("Obagi") for a price of $24 per share in cash, without interest (less any applicable withholding taxes). The Offer expired at midnight, New...
NEW YORK, April 24, 2013 /PRNewswire/ -- Howard P. Milstein, Chairman of American Skin Association (ASA), announced that J. Michael Pearson, Chairman and CEO of Valeant Pharmaceuticals International, Inc., has become a member of the ASA Board of Directors. ASA's main mission is to advance research, champion skin health and drive public awareness regarding skin disease and melanoma/skin cancer. Through its national program of grants and awards, ASA has committed approximately $9...
LAVAL, Quebec, April 24, 2013 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) announced that it has received approval by the Antimonopoly Committee of Ukraine (the "AMC") of its proposed acquisition of Obagi Medical Products, Inc. (NASDAQ: OMPI) ("Obagi") pursuant to a tender offer and subsequent merger. The receipt of the AMC's approval of the acquisition satisfies one of the conditions to consummate the tender offer. As previously announced,...
